Neurostudies.net, LLC

Decatur, Georgia 30033

0 studies enrolling now · 19 studies all time

What they study most

Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Alzheimer's Disease, Cardiovascular Disease, Dementia, Alzheimer Type, Early Alzheimer's Disease, Mild Cognitive Impairment, Parkinson Disease, Prodromal Alzheimer's Disease

Studies at this site

• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Stopped early
• Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment — Completed
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) — Completed
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Completed
• Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease — Completed
• A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia — Completed
• GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease — Completed
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease — Paused
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance — Stopped early
• 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease — Stopped early
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease — Stopped early
• Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy — Completed